What is the appropriate treatment for Candida parapsilosis infection?

Treatment of Candida parapsilosis Infections

An echinocandin (caspofungin, micafungin, or anidulafungin) is the recommended first-line treatment for invasive Candida parapsilosis infections, with fluconazole as an acceptable alternative for non-critically ill patients with azole-susceptible isolates. 1, 2

First-Line Treatment Selection

For Critically Ill Patients or Candidemia

• Initiate an echinocandin immediately as empirical therapy before susceptibility results are available 1, 2:

  • Caspofungin: 70 mg loading dose, then 50 mg daily 2
  • Micafungin: 100 mg daily 2
  • Anidulafungin: 200 mg loading dose, then 100 mg daily 2

• Echinocandins demonstrate strong clinical efficacy for C. parapsilosis bloodstream infections despite naturally higher MICs due to FKS1 polymorphisms 3, 4

• Network meta-analysis shows caspofungin has preferable effects for decreasing 30-day mortality risk in C. parapsilosis infections 4

• Real-world data confirms echinocandins achieve similar mortality outcomes to liposomal amphotericin B even for fluconazole-resistant strains 5

For Non-Critically Ill Patients

• Fluconazole is acceptable as initial therapy if the patient is clinically stable and fluconazole-resistant C. parapsilosis is unlikely 2:
  • Loading dose: 800 mg (12 mg/kg) IV or oral 2
  • Maintenance: 400 mg (6 mg/kg) daily 2

Susceptibility Testing and Treatment Adjustment

• Obtain azole susceptibility testing on all C. parapsilosis isolates 2
• Consider echinocandin susceptibility testing for patients with prior echinocandin exposure or C. parapsilosis infections 2
• Transition from echinocandin to fluconazole within 5-7 days if the patient is clinically stable, isolate is fluconazole-susceptible, and repeat blood cultures are negative 1, 2

Important Caveat on Fluconazole Resistance

• Fluconazole resistance does not independently increase 30-day mortality when appropriate alternative therapy (echinocandins) is used 6
• However, fluconazole-resistant C. parapsilosis is associated with significantly higher 1-year recurrence rates (7-fold increased risk) 6
• Clonal outbreaks of fluconazole-resistant strains are emerging and require heightened surveillance 3

Alternative Agents

Liposomal Amphotericin B

• Use liposomal amphotericin B (3-5 mg/kg daily) for intolerance, limited availability, or resistance to echinocandins and azoles 1, 2
• Demonstrates equivalent efficacy to echinocandins for fluconazole-resistant C. parapsilosis bloodstream infections 5

Voriconazole

• Voriconazole 400 mg (6 mg/kg) twice daily for 2 doses, then 200 mg (3 mg/kg) twice daily is effective but offers no advantage over fluconazole as initial therapy 2
• Consider as step-down oral therapy for selected cases 2

Essential Adjunctive Measures

Source Control

• Remove central venous catheters within 48-72 hours if safely feasible 1, 2
• Early catheter removal is strongly recommended and critical for treatment success 1
• Control any other identified source (drain abscesses, debride infected tissue) 1

Monitoring Requirements

• Obtain daily follow-up blood cultures until three consecutive negative days 1
• If blood cultures remain positive on day 5, repeat search for intravascular or uncontrolled sources 1
• Perform dilated ophthalmological examination within the first week after diagnosis for all non-neutropenic patients with candidemia 2

Site-Specific Considerations

CNS Infections

• Liposomal amphotericin B (usually combined with flucytosine) is strongly recommended based on in-vitro susceptibility 1
• Fluconazole (alone or with flucytosine) for oral consolidation if susceptible 1
• Continue therapy until all signs/symptoms resolve, CSF normalizes, and imaging clears 1

Ocular Candidiasis/Endophthalmitis

• Avoid echinocandins for endophthalmitis due to poor posterior chamber penetration 1
• Use fluconazole or voriconazole systemically for azole-susceptible isolates 1
• Liposomal amphotericin B is an alternative, particularly for resistant organisms 1
• Evaluate need for intravitreal antifungal therapy or vitrectomy with ophthalmology on case-by-case basis 1

Endocarditis

• High-dose echinocandin (caspofungin 150 mg daily, micafungin 150 mg daily, or anidulafungin 200 mg daily) OR liposomal amphotericin B 3-5 mg/kg daily (with or without flucytosine 25 mg/kg four times daily) 2
• Valve replacement is recommended 2
• Continue treatment at least 6 weeks after surgery 2

Duration of Therapy

• Continue treatment for at least 2 weeks after documented clearance of candidemia and resolution of symptoms attributable to candidemia 2
• Longer duration required for complicated infections (endocarditis, osteomyelitis, endophthalmitis) 1, 2